PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-42.34%
Both companies show declining cash positions (-42.34% vs TRAW's -17.44%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-42.34%
Cash + STI yoy ≥ 1.5x TRAW's -17.44%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.91%
Other current assets growth < half of TRAW's -100.00%. David Dodd sees a leaner approach to short-term items.
-41.98%
≥ 1.5x TRAW's -15.95%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-100.00%
Below half TRAW's 40.17%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Other Non-Current Assets Growth compared to TRAW's zero value, indicating worse performance.
-100.00%
Below half of TRAW's 31.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-42.01%
≥ 1.5x TRAW's -15.61%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-48.73%
Above 1.5x TRAW's -23.09%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-46.67%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.33%
Less than half of TRAW's 24.07%. David Dodd sees fewer expansions in other current obligations.
-39.56%
Less than half of TRAW's 11.24%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39.56%
Less than half of TRAW's -82.43%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.24%
Below half TRAW's -8.82%. Michael Burry suspects major net losses or high dividends vs. competitor.
99.72%
Higher AOCI Growth compared to TRAW's zero value, indicating worse performance.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to TRAW's zero value, indicating worse performance.
-51.92%
Below half TRAW's 117.82%. Michael Burry sees potential underperformance in building shareholder capital.
-42.01%
≥ 1.5x TRAW's -15.61%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-46.67%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
42.23%
Above 1.5x TRAW's 17.44%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.